Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Deal Size : Inapplicable
Deal Type : Inapplicable
Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2024
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Deal Size : Inapplicable
Deal Type : Inapplicable